Jonathan James Deeks

Jonathan James Deeks

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Jonathan James Deeks

Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2003 in BMJ
Verified
Journal Article
Open access
PDF file
JHJulian P T Higgins
Julian P T Higgins
STSimon G Thompson
Simon G Thompson
JDJonathan J Deeks
Jonathan J Deeks
DADouglas G Altman
Douglas G Altman
Cochrane Reviews have recently started including the quantity I2 to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice?

12 October 2016 in BMJ
Verified
Journal Article
Open access
PDF file
JSJonathan Ac Sterne
Jonathan Ac Sterne
MHMiguel A Hernán
Miguel A Hernán
BRBarnaby C Reeves
Barnaby C Reeves
JSJelena Savović
Jelena Savović
NBNancy D Berkman
Nancy D Berkman
JHJulian Pt Higgins
Julian Pt Higgins
Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that did not use randomisation to allocate units (individuals or clusters of individuals) to comparison groups. The tool will be particularly useful to those undertaking systematic reviews that include non-randomised studies.

18 October 2011 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
PWPenny Whiting
Penny Whiting
ARAnne W.S. Rutjes
Anne W.S. Rutjes
MWMarie E. Westwood
Marie E. Westwood
SMSusan Mallett
Susan Mallett
JDJonathan J. Deeks
Jonathan J. Deeks
PBPatrick M.M. Bossuyt
Patrick M.M. Bossuyt
In 2003, the QUADAS tool for systematic reviews of diagnostic accuracy studies was developed. Experience, anecdotal reports, and feedback suggested areas for improvement; therefore, QUADAS-2 was developed. This tool comprises 4 domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed in terms of risk of bias, and the first 3 domains are also assessed in terms of concerns regarding applicability. Signalling questions are included to help judge risk of bias. The QUADAS-2 tool is applied in 4 phases: summarize the review question, tailor the tool and produce review-specific guidance, construct a flow diagram for the primary study, and judge bias and applicability. This tool will allow for more transparent rating of bias and applicability of primary diagnostic accuracy studies.

22 July 2011 in BMJ
Verified
Journal Article
Open access
PDF file
JSJonathan A C Sterne
Jonathan A C Sterne
ASAlex J Sutton
Alex J Sutton
JIJ. P. A. Ioannidis
J. P. A. Ioannidis
NTNorma Terrin
Norma Terrin
DJDavid R Jones
David R Jones
JHJulian P T Higgins
Julian P T Higgins
Funnel plots, and tests for funnel plot asymmetry, have been widely used to examine bias in the results of meta-analyses. Funnel plot asymmetry should not be equated with publication bias, because it has a number of other possible causes. This article describes how to interpret funnel plot asymmetry, recommends appropriate tests, and explains the implications for choice of meta-analysis model

23 January 2018 in JAMA
Verified
Journal Article
Closed access
PDF file
MMMatthew D. F. McInnes
Matthew D. F. McInnes
DMDavid Moher
David Moher
BTBrett D. Thombs
Brett D. Thombs
TMTrevor A. McGrath
Trevor A. McGrath
PBPatrick M. Bossuyt
Patrick M. Bossuyt
BWBrian H. Willis
Brian H. Willis
Importance Systematic reviews of diagnostic test accuracy synthesize data from primary diagnostic studies that have evaluated the accuracy of 1 or more index tests against a reference standard, provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability in test accuracy. Objective To develop the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagnostic test accuracy guideline as a stand-alone extension of the PRISMA statement. Modifications to the PRISMA statement reflect the specific requirements for reporting of systematic reviews and meta-analyses of diagnostic test accuracy studies and the abstracts for these reviews. Design Established standards from the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network were followed for the development of the guideline. The original PRISMA statement was used as a framework on which to modify and add items. A group of 24 multidisciplinary experts used a systematic review of articles on existing reporting guidelines and methods, a 3-round Delphi process, a consensus meeting, pilot testing, and iterative refinement to develop the PRISMA diagnostic test accuracy guideline. The final version of the PRISMA diagnostic test accuracy guideline checklist was approved by the group. Findings The systematic review (produced 64 items) and the Delphi process (provided feedback on 7 proposed items; 1 item was later split into 2 items) identified 71 potentially relevant items for consideration. The Delphi process reduced these to 60 items that were discussed at the consensus meeting. Following the meeting, pilot testing and iterative feedback were used to generate the 27-item PRISMA diagnostic test accuracy checklist. To reflect specific or optimal contemporary systematic review methods for diagnostic test accuracy, 8 of the 27 original PRISMA items were left unchanged, 17 were modified, 2 were added, and 2 were omitted. Conclusions and Relevance The 27-item PRISMA diagnostic test accuracy checklist provides specific guidance for reporting of systematic reviews. The PRISMA diagnostic test accuracy guideline can facilitate the transparent reporting of reviews, and may assist in the evaluation of validity and applicability, enhance replicability of reviews, and make the results from systematic reviews of diagnostic test accuracy studies more useful.

18 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
ARAntti Rannikko
Antti Rannikko
MBMarcelo Borghi
Marcelo Borghi
VPValeria Panebianco
Valeria Panebianco
LMLance A. Mynderse
Lance A. Mynderse
CMCaroline M. Moore
Caroline M. Moore
Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.